Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(2):247–254. doi: 10.1054/bjoc.2001.1886

Impaired FHIT expression characterizes serous ovarian carcinoma

K Ozaki 1, T Enomoto 1, K Yoshino 1, M Fujita 1, G S Buzard 3, K Kawano 2, M Yamasaki 2, Y Murata 1
PMCID: PMC2364051  PMID: 11461085

Abstract

The FHIT (fragile histidine triad) gene on chromosome 3p14.2 is a candidate tumour suppressor gene. To define the role of the FHIT gene in the development of ovarian cancer, we have examined 33 ovarian carcinomas, 2 borderline tumours and 10 benign adenomas for the presence of FHIT gene alterations. FHIT transcripts were analysed by RT-PCR and sequencing. Aberrant FHIT transcripts were observed in 5/33 carcinomas (15%) and in 1 of 2 borderline tumours. Loss of normal FHIT transcript was observed in 5/33 carcinomas (15%) but not in 2 borderline tumours or 10 benign adenomas. Allelic losses at D3S1300 and D3S4103, both located within intron 5 of FHIT were detected in 5/24 (21%) and 5/25 (20%) informative ovarian carcinomas, respectively. Expression of Fhit protein was analysed by immunohistochemistry in 44 carcinomas, 19 borderline tumours and 16 benign adenomas. Loss or significantly reduced expression of Fhit protein was observed in 6/44 (14%) ovarian carcinomas but not in any of 19 borderline tumours or 16 benign adenomas. The impaired Fhit protein expression was significantly correlated with the loss of normal FHIT transcription. Most notably, loss of normal FHIT transcript and impaired expression of Fhit protein occurred only in serous adenocarcinomas of grade 2 and 3 (5/15; 33% and 6/19; 32%, respectively). The present data suggest that inactivation of the FHIT gene by loss of expression is one of the important molecular events associated with the genesis of ovarian carcinoma, especially of high-grade serous carcinoma. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: FHIT (fragile histidine triad) gene, ovarian tumour, serous carcinoma

Full Text

The Full Text of this article is available as a PDF (584.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes L. D., Garrison P. N., Siprashvili Z., Guranowski A., Robinson A. K., Ingram S. W., Croce C. M., Ohta M., Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. Biochemistry. 1996 Sep 10;35(36):11529–11535. doi: 10.1021/bi961415t. [DOI] [PubMed] [Google Scholar]
  2. Buttitta F., Marchetti A., Radi O., Bertacca G., Pellegrini S., Gadducci A., Genazzani A. R., Bevilacqua G. Evaluation of FHIT gene alterations in ovarian cancer. Br J Cancer. 1998 Apr;77(7):1048–1051. doi: 10.1038/bjc.1998.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cliby W., Ritland S., Hartmann L., Dodson M., Halling K. C., Keeney G., Podratz K. C., Jenkins R. B. Human epithelial ovarian cancer allelotype. Cancer Res. 1993 May 15;53(10 Suppl):2393–2398. [PubMed] [Google Scholar]
  4. Enomoto T., Fujita M., Cheng C., Nakashima R., Ozaki M., Inoue M., Nomura T. Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer. 1995 Mar;71(3):462–467. doi: 10.1038/bjc.1995.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Enomoto T., Inoue M., Perantoni A. O., Buzard G. S., Miki H., Tanizawa O., Rice J. M. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991 Oct 1;51(19):5308–5314. [PubMed] [Google Scholar]
  6. Enomoto T., Weghorst C. M., Inoue M., Tanizawa O., Rice J. M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 1991 Oct;139(4):777–785. [PMC free article] [PubMed] [Google Scholar]
  7. Fujita M., Enomoto T., Inoue M., Tanizawa O., Ozaki M., Rice J. M., Nomura T. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res. 1994 Dec;85(12):1247–1256. doi: 10.1111/j.1349-7006.1994.tb02937.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fullwood P., Marchini S., Rader J. S., Martinez A., Macartney D., Broggini M., Morelli C., Barbanti-Brodano G., Maher E. R., Latif F. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res. 1999 Sep 15;59(18):4662–4667. [PubMed] [Google Scholar]
  9. Fuqua S. A., Falette N. F., McGuire W. L. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst. 1990 May 16;82(10):858–861. doi: 10.1093/jnci/82.10.858. [DOI] [PubMed] [Google Scholar]
  10. Greenspan D. L., Connolly D. C., Wu R., Lei R. Y., Vogelstein J. T., Kim Y. T., Mok J. E., Muñoz N., Bosch F. X., Shah K. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 1997 Nov 1;57(21):4692–4698. [PubMed] [Google Scholar]
  11. Guo Z., Vishwanatha J. K. Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation. Mol Cell Biochem. 2000 Jan;204(1-2):83–88. doi: 10.1023/a:1007068823848. [DOI] [PubMed] [Google Scholar]
  12. Hahn S. A., Schutte M., Hoque A. T., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996 Jan 19;271(5247):350–353. doi: 10.1126/science.271.5247.350. [DOI] [PubMed] [Google Scholar]
  13. Ji L., Fang B., Yen N., Fong K., Minna J. D., Roth J. A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 1999 Jul 15;59(14):3333–3339. [PubMed] [Google Scholar]
  14. Kisselev L. L., Justesen J., Wolfson A. D., Frolova L. Y. Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules? FEBS Lett. 1998 May 8;427(2):157–163. doi: 10.1016/s0014-5793(98)00420-7. [DOI] [PubMed] [Google Scholar]
  15. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  16. Lounis H., Mes-Masson A. M., Dion F., Bradley W. E., Seymour R. J., Provencher D., Tonin P. N. Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene. 1998 Nov 5;17(18):2359–2365. doi: 10.1038/sj.onc.1202152. [DOI] [PubMed] [Google Scholar]
  17. Lynch M. A., Nakashima R., Song H., DeGroff V. L., Wang D., Enomoto T., Weghorst C. M. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res. 1998 Oct 1;58(19):4227–4232. [PubMed] [Google Scholar]
  18. Mandai M., Konishi I., Kuroda H., Nanbu K., Matsushita K., Yura Y., Hamid A. A., Mori T. Expression of abnormal transcripts of the FHIT (fragile histidine triad) gene in ovarian carcinoma. Eur J Cancer. 1998 Apr;34(5):745–749. doi: 10.1016/s0959-8049(97)10147-2. [DOI] [PubMed] [Google Scholar]
  19. Mao L., Fan Y. H., Lotan R., Hong W. K. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res. 1996 Nov 15;56(22):5128–5131. [PubMed] [Google Scholar]
  20. Morikawa H., Nakagawa Y., Hashimoto K., Niki M., Egashira Y., Hirata I., Katsu K., Akao Y. Frequent altered expression of fragile histidine triad protein in human colorectal adenomas. Biochem Biophys Res Commun. 2000 Nov 11;278(1):205–210. doi: 10.1006/bbrc.2000.3771. [DOI] [PubMed] [Google Scholar]
  21. Obata K., Morland S. J., Watson R. H., Hitchcock A., Chenevix-Trench G., Thomas E. J., Campbell I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998 May 15;58(10):2095–2097. [PubMed] [Google Scholar]
  22. Ohta M., Inoue H., Cotticelli M. G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996 Feb 23;84(4):587–597. doi: 10.1016/s0092-8674(00)81034-x. [DOI] [PubMed] [Google Scholar]
  23. Ozaki K., Enomoto T., Yoshino K., Hongbo S., Nakamura T., Fujita M., Kuragaki C., Sakata M., Kurachi H., Murata Y. fhit Alterations in endometrial carcinoma and hyperplasia. Int J Cancer. 2000 Feb 1;85(3):306–312. doi: 10.1002/(sici)1097-0215(20000201)85:3<306::aid-ijc2>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  24. Panagopoulos I., Thelin S., Mertens F., Mitelman F., Aman P. Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosomes Cancer. 1997 Aug;19(4):215–219. doi: 10.1002/(sici)1098-2264(199708)19:4<215::aid-gcc2>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  25. Saegusa M., Machida D., Okayasu I. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression. Br J Cancer. 2000 Feb;82(3):571–578. doi: 10.1054/bjoc.1999.0966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sard L., Accornero P., Tornielli S., Delia D., Bunone G., Campiglio M., Colombo M. P., Gramegna M., Croce C. M., Pierotti M. A. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8489–8492. doi: 10.1073/pnas.96.15.8489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Stanbridge E. J. Human tumor suppressor genes. Annu Rev Genet. 1990;24:615–657. doi: 10.1146/annurev.ge.24.120190.003151. [DOI] [PubMed] [Google Scholar]
  28. Yoshino K., Enomoto T., Nakamura T., Nakashima R., Wada H., Saitoh J., Noda K., Murata Y. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer. 1998 Apr 13;76(2):176–181. doi: 10.1002/(sici)1097-0215(19980413)76:2<176::aid-ijc2>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  29. Yoshino K., Enomoto T., Nakamura T., Sun H., Ozaki K., Nakashima R., Wada H., Saitoh J., Watanabe Y., Noda K. FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer. 2000 Jan 1;85(1):6–13. doi: 10.1002/(sici)1097-0215(20000101)85:1<6::aid-ijc2>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES